Pfizer Announces Appointment of William Pao as Executive Vice President and Chief Development Officer

New York, USA – March 21, 2024 – Pfizer Inc., a global leader in biopharmaceuticals, is pleased to announce the appointment of Dr. William Pao as the new Executive Vice President and Chief Development Officer, effective immediately. Dr. Pao joins Pfizer from Roche, where he played a pivotal role in research and early development, significantly contributing to the advancement of new molecular entities across multiple therapeutic areas.

In his new role at Pfizer, Dr. Pao will oversee the Global Product Development organization, which is integral to the clinical development and advancement of Pfizer’s innovative medicines pipeline. His extensive experience and leadership are expected to enhance Pfizer's ability to deliver breakthroughs in medicine and treatment solutions.

"Pfizer is committed to leading the way in medical innovation, and the addition of Dr. Pao to our team reinforces our dedication to developing groundbreaking therapies," said Pfizer’s CEO. "His impressive track record in pharmaceutical development and his visionary approach to medicine make him an invaluable asset to our organization."

Dr. Pao expressed his enthusiasm about his new role, stating, "Joining Pfizer presents a unique opportunity to influence the future of healthcare on a global scale. I look forward to contributing to Pfizer’s mission of delivering life-saving and life-enhancing therapies to patients around the world."

Pfizer expects that Dr. Pao's leadership will accelerate the development of new therapies, responding effectively to the fast-evolving healthcare landscape and enhancing the company's impact on global health.

For more information about Pfizer and its global initiatives, please visit Pfizer's website.

(reference)